secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2026-10-19T11:05:19+00:00
Accession:  0001193125-26-424644
Event type: other_material
Sentiment:  negative
Materiality: 0.87
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

EyePoint's LUCIA Phase 3 DURAVYU trial misses primary BCVA non-inferiority endpoint in wet AMD
--------------------------------------------------------------------------------

- LUCIA (475 patients) failed the primary endpoint of statistical non-inferiority in mean BCVA change vs on-label 2 mg aflibercept, despite demonstrating visual improvement.
- Key secondary endpoints met: 38% reduction in treatment burden (nominal p<0.0001), 52% of eyes supplement-free and 71% receiving zero or one supplement through Week 56.
- Favorable safety profile with redosing and strong anatomic control at Week 56, consistent with LUGANO (432 patients), which also missed its primary endpoint.
- EyePoint will complete additional analyses of LUCIA and pooled Phase 3 datasets to assess next steps for DURAVYU in wet AMD.
- DME program on track: pivotal COMO and CAPRI topline data expected Q4 2027; Phase 2 VERONA showed +7.1 letter BCVA gain and 73% supplement-free at Week 24.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/0001193125-26-424644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-20261019.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-424644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer